Table 4

Incremental costs effectiveness ratios of the DNA-based methods compared with each other cholesterol method for screening and identification of FH

StrategyCostEffects (QALY)Incremental costIncremental QALYICER (£/QALY)
Cholesterol£44 57610.89
DNA£50 91824.12£634113.23£479
DNA+CholM-ve DFH£52 67024.28ED*
DNA+CholM-ve DF+PFH£54 79925.18£38811.06£3666
  • * Ruled out by extended dominance (ED).

  • CholM-ve, cascade testing using LDL-C in relatives of mutation-negative index cases; FH, familial hypercholesterolaemia; ICER, cost-effectiveness ratios; QALY, quality-adjusted life-year.